Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 5;9(10):3027-3034.
doi: 10.1016/j.ekir.2024.07.033. eCollection 2024 Oct.

Statin Use and the Progression of Coronary Artery Calcification in CKD: Findings From the KNOW-CKD Study

Jihyun Yang  1 , Kyu-Beck Lee  1 , Hyang Kim  1 , Soo Wan Kim  2 , Yeong Hoon Kim  3 , Su Ah Sung  4 , Jayoun Kim  5 , Kook-Hwan Oh  6 , Ji Yong Jung  7 , Young Youl Hyun  1
Affiliations

Statin Use and the Progression of Coronary Artery Calcification in CKD: Findings From the KNOW-CKD Study

Jihyun Yang et al. Kidney Int Rep. .

Abstract

Introduction: Statin treatment can reduce the risk of cardiovascular disease (CVD). Paradoxically, previous studies have shown that the use of statin is associated with the progression coronary artery calcification (CAC), a well-known predictor of CVD, in individuals with preserved renal function or in patients on dialysis. However, little is known about the association in patients with predialysis chronic kidney disease (CKD). The aim of this study was to characterize the relationship between statin use and progression of CAC in a CKD cohort of Korean adults.

Methods: We analyzed 1177 participants registered in the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD) cohort. Coronary artery calcium score (CACS) was assessed using cardiac computed tomography at baseline and 4 years after enrollment. CAC progression was defined using the Sevrukov method. Statin users were defined as those who used statins for 50% or more of the follow-up period.

Results: The median (interquartile range) of CACS was 0 (0-30.33), and 318 (44.2%) participants had CACS above 0 at baseline. There were 447 (38.0%) statin users and 730 (62.0%) statin nonusers. After 4 years, 374 patients (52.0%) demonstrated CAC progression, which was significantly more frequent in statin users than in statin nonusers (218 [58.3%] vs. 156 [41.7%], P < 0.001). The multivariate-adjusted odds ratio for CAC progression in statin users compared to statin nonusers was 1.78 (1.26-2.50).

Conclusion: Statin use, significantly and independently, is associated with CAC progression in Korean patients with predialysis CKD. Further research is warranted to verify the prognosis of statin-related CAC progression.

Keywords: chronic kidney disease; coronary artery calcification; statin.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Flow diagram for selection of study subjects. CACS, coronary artery calcium score.
Figure 2
Figure 2
The association between statin use and CAC progression by subgroup. BMI, body mass index; CAC, coronary artery calcification; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; PTH, parathyroid hormone.
See this image and copyright information in PMC

References

    1. Gansevoort R.T., Correa-Rotter R., Hemmelgarn B.R., et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–352. doi: 10.1016/S0140-6736(13)60595-4. - DOI - PubMed
    1. Collins R., Reith C., Emberson J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561. doi: 10.1016/S0140-6736(16)31357-5. - DOI - PubMed
    1. Grundy S.M., Stone N.J., Bailey A.L., et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285–e350. doi: 10.1016/j.jacc.2018.11.003. - DOI - PubMed
    1. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455. - DOI - PubMed
    1. Rhee E.J., Kim H.C., Kim J.H., et al. 2018 Guidelines for the management of dyslipidemia in Korea. Korean J Intern Med. 2019;34:1171. doi: 10.3904/kjim.2019.188.e1. - DOI - PMC - PubMed

LinkOut - more resources